

# Pyridoxine Hydrochloride Injection

## UR Guidelines 034

### Policy and Procedure

<b>Department</b>	Medical Management
<b>Purpose</b>	To establish medical necessity guidelines for use of pyridoxine hydrochloride injection
<b>Applicability</b>	VIVA MEDICARE & VIVA COMMERCIAL
<b>Approved</b>	
<b>Approved</b>	Anne-Laura Cook, MD, FACP
<b>Approver Title</b>	Vice President, Clinical Services
<b>Original Effective Date</b>	9/16/25
<b>Revision Date</b>	
<b>Revision Number</b>	
<b>Regulatory Requirement</b>	

Notice: All information herein is proprietary to and sole property of Triton Health Systems, L.L.C. This documentation is for internal use only and may not be re-produced, copied, and/or re-distributed to any persons outside the company without written permission of Triton Health Systems, L.L.C.

**Policy:**

This document applies to VIVA HEALTH, Inc., VIVA HEALTH Administration L.L.C. and Triton Health Systems, L.L.C. hereafter referred to as VIVA HEALTH.

**Pyridoxine Hydrochloride Injection:**

Coverage for this injectable medication must be for an FDA-approved indication. The standard of medical practice regarding the utilization of this treatment must meet all other applicable Medicare statutory and regulatory requirements.

The patient's medical record must clearly document the specific clinical circumstances supporting the medical necessity for services.

**INDICATIONS AND USAGE**

- For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary pyridoxine deficiency (e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia).
- For pyridoxine deficiency as seen in the following: Inadequate dietary intake, Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives.

The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired.

**References**

The above policy is based on the following references:

U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Pyridoxine hydrochloride labeling-package insert, September 2019. Retrieved August 26, 2025, from <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=a56d11c0-b033-4201-85ff-fc710506481a&type=pdf>